High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease

In this prespecified analysis of DANFLU-2, including the largest CKD population ever in an individually randomized vaccine trial, we observed a benefit of HD-IIV vs SD-IIV against hospitalization for influenza or pneumonia, as well as hospitalization for influenza, with suggestion of a greater relative benefit among those with CKD. Furthermore, the beneficial effect of HD-IIV vs SD-IIV on multiple cardiorespiratory outcomes was consistent across participants irrespective of CKD status.

Authors

Institutions

Publication Details

Journal
Journal of the American College of Cardiology
Published
2025-11-26
DOI
https://doi.org/10.1016/j.jacc.2025.10.005
Citations
1
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
1.35
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease

Nino Emanuel Landler, Katja Vu Bartholdy, Brian Lee Claggett, Lothar Wiese et al.
1 citations
Journal of the American College of Cardiology
Influenza Virus Research Studies
1.35
article

High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease

Nino Emanuel Landler, Katja Vu Bartholdy, Brian Lee Claggett, Lothar Wiese, Caroline Espersen, Morten Sengeløv, Matthew M. Loiacono, Lise Witten Davodian, Camilla Ikast Ottosen, Kristoffer Grundtvig Skaarup, Adam Cadovius Femerling Langhoff, Lars Køber, Mats Christian Højbjerg Lassen, Gunnar Gislason, Jens‐Ulrik Stæhr Jensen, Marine Dufournet, Filip Soeskov Davidovski, Lisa Steen Duus, Carsten Schade Larsen, Anne Bjerg Nielsen, Daniel Modin, Maria Dons, Cyril Jean‐Marie Martel, Rebecca C. Harris, Michael Dalager‐Pedersen, Martin Landray, Niklas Dyrby Johansen, Tor Biering‐Sørensen, Pradeesh Sivapalan, Katrine Feldballe Bernholm, Julie Borchsenius, Frederik Holme Fussing, Anne Jensen, Lykke Larsen, Scott D Solomon
article en
1 citations

Abstract

In this prespecified analysis of DANFLU-2, including the largest CKD population ever in an individually randomized vaccine trial, we observed a benefit of HD-IIV vs SD-IIV against hospitalization for influenza or pneumonia, as well as hospitalization for influenza, with suggestion of a greater relative benefit among those with CKD. Furthermore, the beneficial effect of HD-IIV vs SD-IIV on multiple cardiorespiratory outcomes was consistent across participants irrespective of CKD status.

Journal of the American College of CardiologyVol. 86(25)
Statens Serum Institut (DK), University of Copenhagen (DK), Brigham and Women's Hospital (US), Harvard University (US), Aalborg University Hospital (DK), Odense University Hospital (DK), Aarhus University Hospital (DK), Copenhagen University Hospital (DK), Gentofte Hospital (DK), Sanofi (France) (FR), University of Oxford (GB), Zealand University Hospital (DK), Heart Foundation (US), University of Delaware (US)
Openalex Percentile: Top 14%
Influenza Virus Research Studies
1.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.